Resource Access for the Bridging Interventional Development Gaps Program
(X01)
The high cost of translating therapeutic discoveries into
clinically-available agents can deter the development of promising
therapeutics. When private sector resources are limited, BrIDGs’ in-kind
services could help researchers span the gap between the preclinical and
clinical stages of therapy development and continue to evaluate agents that may
improve the standard of care for patients with a variety of diseases and
disorders. The purpose of this Funding Opportunity Announcement (FOA) is to
invite investigators to apply for access to government-funded contract
resources needed for the preclinical development of therapeutic agents.
Applications are accepted for the development of
the following therapeutic agents:
- Small
molecules
- Peptides
- Oligonucleotides
- Gene
vectors
- Recombinant
proteins
- Monoclonal
antibodies
Potential therapies for any disease or disorder
may be submitted. Vaccines, devices and diagnostic agents are ineligible for
the program. Only lead agents with demonstrated pharmacological activity in an
appropriate disease model will be considered for development.
Application open date: March
3, 2012
